TMCnet News
Global Heart Failure Drugs Market 2018-2022 - Amgen, AstraZeneca, Bayer, and Novartis are Dominating the Market - ResearchAndMarkets.comThe "Global Heart Failure Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. Global heart failure drugs market to grow at a CAGR of 10.46% during the period 2018-2022. The latest trend gaining momentum in the market is investment inclination toward developing countries. Countries such as India, China, and Brazil are turning out to be some of the most attractive countries for pharmaceutical companies across the globe. Many factors such as huge share of global population and rising geriatric population are leading to the high growth of healthcare sector in the developing countries. In addition, the rising cases of lifestyle disorders such as obesity and diabetes also contribute to higher eart failure cases in the region. One of the major drivers for this market is rising geriatric population. A large number of health problems are associated with the rising age, and CVDs are major among them. As a person gets older, the blood vessels become less flexible, thus making it difficult for the blood to flow through them. Rising age accompanied by other factors such as lifestyle-oriented diseases and smoking increases the risk of CVDs, especially heart failure. Heart failure in the geriatric population will continue to be a rising health burden globally, as this population represents the majority of the heart failure patients. Hence, rising geriatric population drives the demand for heart failure drugs during the forecast period. Key Vendors
Other Prominent Vendors
For more information about this report visit https://www.researchandmarkets.com/research/jwpjls/global_heart?w=4 View source version on businesswire.com: http://www.businesswire.com/news/home/20180117006330/en/ |
